迪瑞醫療(300396.SZ)：公司實控人將變更為中國華潤有限公司 明起復牌
格隆匯 8 月 24日丨迪瑞醫療(300396.SZ)公佈，2020年8月24日，公司控股股東晉江瑞發投資有限公司(“晉江瑞發”)及一致行動人宋勇、宋潔與深圳市華德欣潤股權投資企業(有限合夥)(“華德欣潤”)簽署了《晉江瑞發投資有限公司與深圳市華德欣潤股權投資企業(有限合夥)及宋勇、宋潔關於迪瑞醫療科技股份有限公司之股權轉讓協議》，以及宋勇與華德欣潤簽署了《關於放棄行使表決權的協議》。
晉江瑞發將持有迪瑞醫療7728.84萬股股份及上市公司控制權轉讓予華德欣潤，占上市公司總股本比例為28%【占上市公司總股本(剔除公司回購專用賬户中的股份數量)比例為28.19%】。
同時，約定如於上述股份交割完成時，華德欣潤所持上市公司股份比例高於宋勇、宋潔及其一致行動人持有上市公司股份比例但是股份比例差距低於7%，宋勇自上述股份交割完成之日起放棄其所持上市公司部分或全部股份對應的表決權，以實現華德欣潤可實際支配表決權比例比宋勇、宋潔及其一致行動人可實際可支配的上市公司表決權比例高7%。
同日，晉江瑞發、宋勇、宋潔與廣東廣恆順投資有限公司(“廣恆順”)簽署了《晉江瑞發投資有限公司與廣東廣恆順投資有限公司及宋勇、宋潔關於迪瑞醫療科技股份有限公司之股權轉讓協議》。晉江瑞發將持有公司3312.36萬股股份轉讓給廣恆順，佔公司總股本的比例為12%【佔公司總股本(剔除公司回購專用賬户中的股份數量)的比例為12.08%】。
同日，晉江瑞發與易湘蘋、宋潔及宋超簽署了《關於迪瑞醫療科技股份有限公司之股權轉讓協議》。晉江瑞發將其持有的迪瑞醫療3808.8萬股流通股份，佔迪瑞醫療總股本的13.80%【佔迪瑞醫療總股本(剔除公司回購專用賬户中的股份數量)比例為13.89%】，轉讓給易湘蘋、宋潔及宋超；易湘蘋受讓2094.84萬股，佔迪瑞醫療總股本7.59%【佔迪瑞醫療總股本(剔除公司回購專用賬户中的股份數量)比例為7.64%】；宋潔受讓1333.08萬股，佔迪瑞醫療總股本4.83%【佔迪瑞醫療總股本(剔除公司回購專用賬户中的股份數量)比例為4.86%】；宋超受讓380.88萬股，佔迪瑞醫療總股本1.38%【佔迪瑞醫療總股本(剔除公司回購專用賬户中的股份數量)比例為1.39%】。
若股權轉讓事項完成後，公司的控股股東將由晉江瑞發變更為華德欣潤。公司實際控制人將由宋勇變更為中國華潤有限公司。
經公司向深圳證券交易所申請，公司股票自2020年8月25日上午開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
